Cargando…
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline
PURPOSE: In Alzheimer’s disease (AD), increased metabolism of monoamines by monoamine oxidase type B (MAO-B) leads to the production of toxic reactive oxygen species (ROS), which are thought to contribute to disease pathogenesis. Inhibition of the MAO-B enzyme may restore brain levels of monoaminerg...
Autores principales: | Sturm, Stefan, Forsberg, Anton, Nave, Stephane, Stenkrona, Per, Seneca, Nicholas, Varrone, Andrea, Comley, Robert A., Fazio, Patrik, Jamois, Candice, Nakao, Ryuji, Ejduk, Zbigniew, Al-Tawil, Nabil, Akenine, Ulrika, Halldin, Christer, Andreasen, Niels, Ricci, Benedicte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5281649/ https://www.ncbi.nlm.nih.gov/pubmed/27633250 http://dx.doi.org/10.1007/s00259-016-3510-6 |
Ejemplares similares
-
Test-retest reproducibility of [(11)C]-l-deprenyl-D(2) binding to MAO-B in the human brain
por: Arakawa, Ryosuke, et al.
Publicado: (2017) -
PET Imaging of VMAT2 with the Novel Radioligand [(18)F]FE-DTBZ-d4 in Nonhuman Primates: Comparison with [(11)C]DTBZ and [(18)F]FE-DTBZ
por: Nag, Sangram, et al.
Publicado: (2021) -
[(18)F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study
por: Kerstens, Vera S., et al.
Publicado: (2023) -
Sembragiline in Moderate Alzheimer’s Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD)
por: Nave, Stephane, et al.
Publicado: (2017) -
High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort
por: Fazio, Patrik, et al.
Publicado: (2020)